| Methods and compositions for inducing hematopoietic cell differentiation |
2023-6-20 |
2023-7-13 |
|
| Genomic engineering of pluripotent cells |
2023-5-03 |
2023-5-18 |
|
| Methods and compositions for inducing hematopoietic cell differentiation |
2023-3-14 |
2023-7-06 |
|
| Compositions and methods for immune cell modulation in adoptive immunotherapies |
2023-3-14 |
2023-4-13 |
|
| Platform for the induction & maintenance of ground state pluripotency |
2023-2-16 |
2023-3-16 |
|
| Enhanced stem cell composition |
2023-2-08 |
2023-4-12 |
|
| Cells with enhanced immunoregulatory properties and methods for use and … |
2023-1-26 |
2023-4-11 |
|
| Compositions and methods for immune cell modulation in adoptive immunotherapies |
2023-1-04 |
2023-3-14 |
|
| Engineered effector cells for trafficking of allogeneic cell therapies in solid … |
2022-11-07 |
2023-5-11 |
|
| Engineered effector cells and methods of enhancing ubiquitous targeting of … |
2022-11-07 |
2023-5-11 |
|
| Effector cells and use thereof for allogeneic adoptive cell therapies in solid … |
2022-10-20 |
2023-4-27 |
|
| Off-the-shelf ipsc-derived car-nk cell as monotherapy and in combination with … |
2022-8-18 |
2023-2-23 |
|
| Protected effector cells and use thereof for allogeneic adoptive cell therapies |
2022-7-01 |
2023-1-05 |
|
| Compositions and methods for immune cell modulation in adoptive immunotherapies |
2022-6-29 |
2022-9-06 |
|
| Enhancement of ipsc-derived effector immune cell using small compounds |
2022-6-02 |
2022-8-01 |
|
| Improved methods of treating ischemia |
2022-4-21 |
2022-6-23 |
|
| Cell culture platform for single cell sorting and enhanced reprogramming of … |
2022-4-13 |
2022-6-30 |
|
| Improved reprogramming method and cell culture platform |
2022-4-04 |
2022-6-02 |
|
| Enhanced chimeric antigen receptor for immune effector cell engineering and use … |
2022-4-03 |
2022-6-01 |
|
| Multi-targeting effector cells and use thereof |
2022-3-17 |
2022-5-01 |
|
| Immune effector cell engineering and use thereof |
2022-1-13 |
2022-3-01 |
|
| Off-the-shelf ipsc-derived nk cell therapy for hematological cancer treatment |
2021-12-03 |
2022-6-09 |
|
| Multiple engineered ipscs and immune effector cells targeting solid tumors |
2021-11-04 |
2023-8-18 |
|
| Engineered ipscs and durable immune effector cells |
2021-11-04 |
2023-7-07 |
|
| Multiplexed engineered iPSCs and immune effector cells targeting solid tumors |
2021-11-04 |
2023-6-29 |
|
| Engineered ipsc and immune effector cells for heterogenous tumor control |
2021-11-04 |
2022-5-12 |
|
| Engineered ipscs and immune effector cells for heterogeneous tumor control |
2021-11-04 |
2023-8-18 |
|
| Improved hematopoietic stem and progenitor cell therapy |
2021-10-22 |
2022-1-14 |
|
| Engineered ipsc and armed immune effector cells |
2021-10-08 |
2023-6-01 |
|
| Engineered ipscs and armed immune effector cells |
2021-10-08 |
2023-7-18 |
|
| Improved reprogramming, maintenance and preservation for induced pluripotent … |
2021-10-01 |
2023-5-11 |
|
| Cd3 reconstitution in engineered ipsc and immune effector cells |
2021-9-30 |
2021-12-01 |
|
| Combining ipsc-derived effector cell types for immunotherapy use |
2021-6-18 |
2021-12-23 |
|
| Immunotherapies using enhanced ipsc derived effector cells |
2021-6-01 |
2021-7-29 |
|
| Improved hematopoietic stem and progenitor cell therapy |
2021-3-23 |
2021-4-15 |
|
| Minimal volume reprogramming of mononuclear cells |
2021-2-23 |
2021-7-01 |
|
| Enhanced immune effector cells and use thereof |
2021-2-19 |
2021-6-17 |
|
| Cell potency assay for therapeutic potential |
2020-11-12 |
2021-11-04 |
|
| Enhanced chimeric antigen receptor for immune effector cell engineering and use … |
2020-10-19 |
2021-4-22 |
|
| Engineered immune effector cells and use thereof |
2020-9-24 |
2020-11-30 |
|
| Compositions comprising cyclic amp enhancers and/or ep ligands, and methods for … |
2020-8-21 |
2020-11-19 |
|
| Immunotherapies using enhanced ipsc derived effector cells |
2020-6-07 |
2020-7-30 |
|
| Cellular reprogramming using temporal and transient plasmid vector expression … |
2020-4-07 |
2020-5-31 |
|
| Stem cell culture media and methods of enhancing cell survival |
2020-1-07 |
2020-6-11 |
|
| IMMUNOTHERAPIES USING ENHANCED IPSC-DERIVED EFFECTOR CELLS |
2019-11-25 |
2021-10-05 |
|
| Compositions and methods for immune cell modulation in adoptive immunotherapies |
2018-7-19 |
2020-5-27 |
|
| Composition and methods for inducing myeloid suppressive cells and use thereof |
2018-6-13 |
2020-4-02 |
|
| Modulation of t lymphocytes |
2018-6-04 |
2018-10-05 |
|
| Wnt compositions and therapeutic uses of such compositions |
2016-3-10 |
2016-3-31 |
|
| Compounds to treat hearing loss |
2014-9-05 |
2015-5-07 |
|
| Biovessels |
2013-6-27 |
2013-10-31 |
|
| Small molecule compounds to treat hearing loss |
2013-2-22 |
2015-1-22 |
|
| Cardiotrophin related molecules for enhanced therapeutics |
2012-2-01 |
2013-12-11 |
|
| Wnt compositions and therapeutic uses of such compositions |
2012-1-11 |
2016-8-02 |
2016-8-02 |
| Oxysterol compounds |
2011-8-19 |
2012-4-12 |
|
| Oxysterol compounds |
2011-8-19 |
2012-4-12 |
|
| Oxysterol compounds |
2011-8-19 |
2012-2-23 |
|
| Pharmaceutical compositions to treat fibrosis |
2011-4-06 |
2013-10-17 |
|
| Improved reprogramming compositions |
2010-12-21 |
2011-11-10 |
|
| Suicide ready cells |
2010-9-16 |
2011-7-21 |
|
| Cell-based compositions and uses thereof |
2010-9-09 |
2011-3-17 |
|
| Treatment of muscle disease characterized by insulin resistance |
2010-5-18 |
2010-11-25 |
|
| Reprogramming compositions and methods of using the same |
2010-3-19 |
2011-2-24 |
|
| Methods for reprogramming cells to a pluripotent state and therapeutic … |
2008-12-23 |
2009-7-09 |
|
| Imunoterapias com o uso de células efetoras derivadas de ipsc intensificadas |
2019-11-25 |
2021-10-05 |
|